{"id":44289,"date":"2022-05-24T18:01:52","date_gmt":"2022-05-24T16:01:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/"},"modified":"2022-05-24T18:01:52","modified_gmt":"2022-05-24T16:01:52","slug":"activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/","title":{"rendered":"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Digital Surgery Pioneer Conducts 40-Patient Study with ActivSight<\/i>\u2122<i> Intraoperative Imaging Module to Demonstrate Advanced Visualization Use Cases <\/i><i>in the Operating Room<\/i>\n<\/p>\n<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.activsurgical.com&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Activ+Surgical&amp;index=1&amp;md5=708c859e8001b4cd1cdc4e0ba835ddcf\" rel=\"nofollow noopener\" shape=\"rect\">Activ Surgical<\/a><sup>\u2122<\/sup>, a digital surgery pioneer, today announced the successful completion of an Institutional Review Board (IRB) study using its ActivSight\u2122 intraoperative imaging module at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo (UB) in New York. The 40-patient study was led by principal investigator <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fubmdsurgery.com%2Four-team%2Fchristina-sanders-do-facs%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Dr.+Christina+Sanders&amp;index=2&amp;md5=e8ff4f1e6cee52849c0bc4ff550a49ee\" rel=\"nofollow noopener\" shape=\"rect\">Dr. Christina Sanders<\/a>, medical director of ECMC Synergy Bariatrics for UB, and demonstrated how the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.activsurgical.com%2Fnews%2Ffda-clearance&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=FDA-cleared&amp;index=3&amp;md5=3f4db39ef95a6f56fd850bee2b67b152\" rel=\"nofollow noopener\" shape=\"rect\">FDA-cleared<\/a> ActivSight imaging module can provide real time, on-demand insights and intraoperative visual data and images not currently available to surgeons through existing technologies.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220524005285\/en\/1451173\/5\/Activ_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220524005285\/en\/1451173\/21\/Activ_logo.jpg\"><\/a><\/p>\n<p>\nDr. Sanders was joined by peers from UB during this IRB study, including Dr. Steven Schwaitzberg, Dr. Aaron Hoffman, Dr. John Ortolani, Dr. John Butsch, Dr. Alan Posner, Dr. Matthew Burtstein and Dr. Marissa Novack. In addition, Dr. Ajay Panchal, Dr. Mark Falvo and Dr. Jeffrey Visco from Millard Fillmore Suburban Hospital also participated in the study.\n<\/p>\n<p>\nDuring the study, Dr. Sanders and her colleagues conducted a variety of procedures using the ActivSight imaging module on patients undergoing elective laparoscopic and robotic-assisted bariatric and colorectal anastomoses and cholecystectomies with the goal of improving patient safety by reducing adverse complications through augmented visual intelligence. The imaging module is an easy-to-adapt platform that seamlessly attaches to today\u2019s laparoscopic systems providing real time, on demand insights, integrated into standard monitors. The study incorporated the use of the Activ Surgical intraoperative surgical intelligence and the proprietary ActivPerfusion\u2122 visualization mode that allows for dye-free detection and display of tissue perfusion and real-time imperceptible latency.\n<\/p>\n<p>\n\u201cMy peers and I are very pleased with the results of this IRB study using Activ Surgical enhanced visualization,\u201d said Dr. Sanders. \u201cThe technology was easy to use and allowed us to see critical elements, such as blood flow and tissue perfusion, that were previously impossible to see with repeatable accuracy during procedures. The potential impact of the ActivSight imaging module and Activ Surgical visualization technology to improve patient safety is incredibly promising.\u201d\n<\/p>\n<p>\n\u201cImplementing new technologies into the OR is historically very difficult to do,\u201d said Dr. Steven Schwaitzberg, SUNY Distinguished Service Professor and Chairman of Surgery in the Jacobs School at UB. \u201cI was impressed by the ActivSight imaging module\u2019s capabilities, specifically its ability to enhance visualization capabilities during surgical procedures. All of the surgeons involved in this study are excited about the promise of the Activ Surgical technology and the potential impact it may have on surgical outcomes.\u201d\n<\/p>\n<p>\n\u201cCompleting this IRB study is a significant milestone for Activ Surgical that validates our technology as we prepare for global commercialization of the ActivSight imaging module,\u201d said Todd Usen, chief executive officer, Activ Surgical. \u201cWe are incredibly thankful for the work Dr. Sanders and her colleagues have completed at UB and are encouraged by the successes they experienced in the OR using our technology. We believe our platform has great potential to improve patient outcomes and safety in the OR and help to democratize surgical care across the globe.\u201d\n<\/p>\n<p>\nActiv Surgical is offering early access to the ActivSight imaging module to select customers now, with full commercial availability coming later this year. For more information about the company and its proprietary technology, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.activsurgical.com&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=www.activsurgical.com&amp;index=4&amp;md5=946514972d5591bc0ed386701ff6d570\" rel=\"nofollow noopener\" shape=\"rect\">www.activsurgical.com<\/a>.\n<\/p>\n<p>\n<b>About Activ Surgical<\/b>\n<\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.activsurgical.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Activ+Surgical&amp;index=5&amp;md5=9aaf579aa14088f7f4c3dc0ea953f359\" rel=\"nofollow noopener\" shape=\"rect\">Activ Surgical<\/a> is the pioneering digital surgery company that completed the world\u2019s first autonomous robotic surgery of soft tissue in 2018. The company is revolutionizing surgical vision, enabling a future of augmented reality-based and artificial intelligence-driven surgery that is safe, smart, and accessible to all. Its patent-protected surgical software platform&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.activsurgical.com%2F%23Technology&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=ActivEdge%26%238482%3B&amp;index=6&amp;md5=56e2a2db966575270904d5a6876383eb\" rel=\"nofollow noopener\" shape=\"rect\">ActivEdge\u2122<\/a>&#8211;is being designed to reduce unintended and preventable surgical errors by enhancing a surgeon\u2019s intraoperative decision making via the aggregation of surgical data from around the world. Activ Surgical is privately held, and backed by <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.dnscap.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=DNS+Capital&amp;index=7&amp;md5=49379b4ea417acc58aa42f1afe4285b5\" rel=\"nofollow noopener\" shape=\"rect\">DNS Capital<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cotacapital.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Cota+Capital&amp;index=8&amp;md5=b0e9f7b325e569893e8ebe16f50e04ec\" rel=\"nofollow noopener\" shape=\"rect\">Cota Capital<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.bamfunds.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=BAM+Funds&amp;index=9&amp;md5=3277df86617aa732af849da3f493b1d0\" rel=\"nofollow noopener\" shape=\"rect\">BAM Funds<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gpv.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=GreatPoint+Ventures+%28GPV%29&amp;index=10&amp;md5=93229887811c05ac016dfecaadccc0f3\" rel=\"nofollow noopener\" shape=\"rect\">GreatPoint Ventures (GPV)<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.av.co%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=ARTIS+Ventures&amp;index=11&amp;md5=1224e1339260514bc2e0b3b97d749e24\" rel=\"nofollow noopener\" shape=\"rect\">ARTIS Ventures<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lrvhealth.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=LRVHealth&amp;index=12&amp;md5=661f48f59c3a27cf91537081338a0b8a\" rel=\"nofollow noopener\" shape=\"rect\">LRVHealth<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.taocap.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Tao+Capital+Partners&amp;index=13&amp;md5=d712c82ed3bbb048fb0f47e0f89ebec7\" rel=\"nofollow noopener\" shape=\"rect\">Tao Capital Partners<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.magnetar.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Magnetar+Capital&amp;index=14&amp;md5=9c8c504022c918bcb92533cd2879e9bd\" rel=\"nofollow noopener\" shape=\"rect\">Magnetar Capital<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=NVIDIA&amp;index=15&amp;md5=de228c40f5ee2a78a649016a8ef4f424\" rel=\"nofollow noopener\" shape=\"rect\">NVIDIA<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Frtf.vc%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Rising+Tide+VC&amp;index=16&amp;md5=5f32ceddda1cfaf902e7ca3c85564ddb\" rel=\"nofollow noopener\" shape=\"rect\">Rising Tide VC<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.hikmaventures.com%2Fhome%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Hikma+Ventures&amp;index=17&amp;md5=004366eec75182b35ecbc352ddfd2149\" rel=\"nofollow noopener\" shape=\"rect\">Hikma Ventures<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fmintventures.bio%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=MINT+Venture+Partners&amp;index=18&amp;md5=b0451141824f4b89a0b93aedccc487bd\" rel=\"nofollow noopener\" shape=\"rect\">MINT Venture Partners<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.avgfunds.com%2Fcastor-ventures%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Castor+Ventures&amp;index=19&amp;md5=4398ad9e2151e5032bd2277d97c12222\" rel=\"nofollow noopener\" shape=\"rect\">Castor Ventures<\/a>, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.sonyinnovationfund.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=SONY+Innovation+Fund&amp;index=20&amp;md5=74b0c0da475fafc056cda4fd4cf22946\" rel=\"nofollow noopener\" shape=\"rect\">SONY Innovation Fund<\/a>, and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.dreamonevision.com%2F&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=Dream+One+Vision&amp;index=21&amp;md5=7552f0240154ed777209e90de3ddfe66\" rel=\"nofollow noopener\" shape=\"rect\">Dream One Vision<\/a>. Learn more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.activsurgical.com&amp;esheet=52728616&amp;newsitemid=20220524005285&amp;lan=en-US&amp;anchor=www.activsurgical.com&amp;index=22&amp;md5=c1387e55535a3b008b4e8e6abd859d57\" rel=\"nofollow noopener\" shape=\"rect\">www.activsurgical.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nHeath Meyer<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;&#108;&#x74;&#x6f;&#58;&#x68;&#x65;&#97;&#x74;&#x68;&#64;&#x74;&#x65;&#97;&#x6d;&#x73;&#101;&#x69;&#x73;&#109;&#x69;&#x63;&#46;&#x63;&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x68;&#101;&#97;t&#x68;&#x40;&#116;e&#x61;&#x6d;&#115;ei&#x73;&#109;&#105;c&#x2e;&#x63;&#111;m<\/a><br \/>858-768-1527\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Digital Surgery Pioneer Conducts 40-Patient Study with ActivSight\u2122 Intraoperative Imaging Module to Demonstrate Advanced Visualization Use Cases in the Operating Room BOSTON&#8211;(BUSINESS WIRE)&#8211;Activ Surgical\u2122, a digital surgery pioneer, today announced the successful completion of an Institutional Review Board (IRB) study using its ActivSight\u2122 intraoperative imaging module at the Jacobs School of Medicine and Biomedical Sciences &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44289","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Digital Surgery Pioneer Conducts 40-Patient Study with ActivSight\u2122 Intraoperative Imaging Module to Demonstrate Advanced Visualization Use Cases in the Operating Room BOSTON&#8211;(BUSINESS WIRE)&#8211;Activ Surgical\u2122, a digital surgery pioneer, today announced the successful completion of an Institutional Review Board (IRB) study using its ActivSight\u2122 intraoperative imaging module at the Jacobs School of Medicine and Biomedical Sciences ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-24T16:01:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220524005285\/en\/1451173\/21\/Activ_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo\",\"datePublished\":\"2022-05-24T16:01:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/\"},\"wordCount\":701,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005285\\\/en\\\/1451173\\\/21\\\/Activ_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/\",\"name\":\"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005285\\\/en\\\/1451173\\\/21\\\/Activ_logo.jpg\",\"datePublished\":\"2022-05-24T16:01:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005285\\\/en\\\/1451173\\\/21\\\/Activ_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220524005285\\\/en\\\/1451173\\\/21\\\/Activ_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/","og_locale":"en_US","og_type":"article","og_title":"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo - Pharma Trend","og_description":"Digital Surgery Pioneer Conducts 40-Patient Study with ActivSight\u2122 Intraoperative Imaging Module to Demonstrate Advanced Visualization Use Cases in the Operating Room BOSTON&#8211;(BUSINESS WIRE)&#8211;Activ Surgical\u2122, a digital surgery pioneer, today announced the successful completion of an Institutional Review Board (IRB) study using its ActivSight\u2122 intraoperative imaging module at the Jacobs School of Medicine and Biomedical Sciences ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-24T16:01:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220524005285\/en\/1451173\/21\/Activ_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo","datePublished":"2022-05-24T16:01:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/"},"wordCount":701,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220524005285\/en\/1451173\/21\/Activ_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/","url":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/","name":"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220524005285\/en\/1451173\/21\/Activ_logo.jpg","datePublished":"2022-05-24T16:01:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220524005285\/en\/1451173\/21\/Activ_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220524005285\/en\/1451173\/21\/Activ_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/activ-surgical-successfully-completes-institutional-review-board-study-at-university-at-buffalo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Activ Surgical Successfully Completes Institutional Review Board Study at University at Buffalo"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44289"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44289\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}